Matrixx Initiatives Inc. (Zicam), Scottsdale, AZ 483 issued 5/28/2009 (1 page)

On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

New Drug/Misbranded

It has become increasingly clear that new approach methodologies (NAMs)—when combined with knowledge of the pathway, results of pharmacology studies, and other relevant data—may offer ways to reduce animal testing.

Science-based health and safety information you can trust.

Unapproved New Drugs/Misbranded